



Jennifer Caswell-Jin

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICES

900 Blake Wilbur Dr

3rd Fl MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 497-6813

Bio

BIO

Jennifer Caswell-Jin, MD is an Assistant Professor of Medicine (Oncology) specializing in breast cancer care and research. She received her medical degree from Harvard Medical School in 2010, completed her internal medicine residency at the University of California, San Francisco in 2013, and completed her clinical fellowship in medical oncology at Stanford Hospital & Clinics in 2017. Her clinical translational research program is aimed at developing personalized approaches to care that improve the outcomes of people with breast cancer.

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- AACR Associate Member Award, San Antonio Breast Cancer Symposium (2018)
- Physician Scientist Training Award, Damon Runyon Cancer Research Foundation (2017)
- Postdoctoral Fellowship Award, Susan G. Komen (2017)
- ASCO Young Investigator Award, Conquer Cancer Foundation (2017)
- SCI Fellowship Award, Stanford Cancer Institute (2017)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2013)
- Residency: UCSF Internal Medicine Residency (2013) CA
- Medical Education: Harvard Medical School (2010) MA

- A.B., Harvard College , Biological Anthropology (2006)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.

CLINICAL TRIALS

- Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies, Recruiting
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.** *JNCI cancer spectrum*
Kurian, A. W., Abrahamse, P., Hamilton, A. S., Caswell-Jin, J. L., Gomez, S. L., Hofer, T. J., Ward, K. C., Katz, S. J.
2022
- **Association of germline genetic testing results with chemotherapy regimens received by women with early-stage breast cancer.**
Kurian, A. W., Abrahamse, P., Caswell Jin, J., Hamilton, A. S., Hofer, T., Ward, K. C., Katz, S.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017.**
Caswell-Jin, J., Sun, L., Munoz, D., Lu, Y., Li, Y., Huang, H., Hampton, J. M., Song, J., Jayasekera, J., Schechter, C., Alagoz, O., Stout, N. K., Trentham-Dietz, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.**
Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J., Patel, P. H., Rosen, E.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population.** *Breast cancer research and treatment*
Caswell-Jin, J. L., Shafae, M. N., Xiao, L., Liu, M., John, E. M., Bondy, M. L., Kurian, A. W.
2022
- **Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*
Bean, G. R., Najjar, S., Shin, S. J., Hosfield, E. M., Caswell-Jin, J. L., Urisman, A., Jones, K. D., Chen, Y., Krings, G.
2022
- **Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.** *Breast cancer research and treatment*
Parikh, D. A., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., Karin, M. R., Wapnir, I. L., Patel, M. I., Sledge, G. W., Caswell-Jin, J. L.
2022
- **Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.**
Afghahi, A., Marsh, S., Winchester, A., Gao, D., Parris, H., Axell, L., Ellisen, L. W., Hofstatter, E., Kurian, A. W., Wood, M., Zakalik, D., Mullin, C., Caswell-Jin, et al

LIPPINCOTT WILLIAMS & WILKINS.2021

- **Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response** *NATURE CANCER*
McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., Zoeller, J., Press, M. F., Slamon, et al
2021; 2 (4): 400-+
- **Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.** *Nature cancer*
McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., Zoeller, J., Press, M. F., Slamon, et al
2021; 2 (4): 400-413
- **Androgen receptor agonists as breast cancer therapeutics.** *Nature medicine*
Caswell-Jin, J. L., Curtis, C.
2021
- **Molecular Heterogeneity and Evolution in Breast Cancer** *Annual review of cancer biology*
Caswell-Jin, J. L., Lorenz, C., Curtis, C.
2021; 5: 79-94
- **Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.** *JCO clinical cancer informatics*
Caswell-Jin, J. L., Callahan, A., Purington, N., Han, S. S., Itakura, H., John, E. M., Blayney, D. W., Sledge, G. W., Shah, N. H., Kurian, A. W.
2021; 5: 600-614
- **Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.** *Cancer*
Kurian, A. W., Hughes, E., Simmons, T., Bernhisel, R., Probst, B., Meek, S., Caswell-Jin, J. L., John, E. M., Lanchbury, J. S., Slavin, T. P., Wagner, S., Gutin, A., Rohan, et al
2021
- **Understanding patient perspectives on window of opportunity clinical trials.**
Parikh, D., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., Sledge, G. W., Caswell-Jin, J.
AMER SOC CLINICAL ONCOLOGY.2020
- **Performance of the IBIS/Tyrer-Cuzick (TC) Model by race/ethnicity in the Women's Health Initiative.**
Kurian, A. W., Hughes, E., Bernhisel, R., Probst, B., Lanchbury, J., Wagner, S., Gutin, A., Caswell-Jin, J., Rohan, T. E., Shadyab, A. H., Manson, J. E., Lane, D., Stefanick, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.**
Caswell-Jin, J., Callahan, A., Purington, N., Han, S. S., Itakura, H., Sledge, G. W., Shah, N., Kurian, A. W.
AMER SOC CLINICAL ONCOLOGY.2020
- **Characterizing the tumor and immune microenvironment through treatment to predict response to neoadjuvant HER2-targeted therapy using the Digital Spatial Profiler**
McNamara, K., Caswell-Jin, J. L., Ma, Z., Zoeller, J. J., Kriner, M., Zhou, Z., Reeves, J., Hoang, M., Beechem, J., Slamon, D. J., Press, M. F., Brugge, J., Hurvitz, et al
AMER ASSOC CANCER RESEARCH.2020
- **Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial**
Caswell-Jin, J. L., McNamara, K. L., Dering, J., Chen, H., Dichmann, R., Perez, A., Patel, R., Kotler, E., Zoeller, J. J., Brugge, J. S., Press, M. F., Slamon, D. J., Curtis, et al
AMER ASSOC CANCER RESEARCH.2020
- **Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).** *Nature communications*
Hurvitz, S. A., Caswell-Jin, J. L., McNamara, K. L., Zoeller, J. J., Bean, G. R., Dichmann, R., Perez, A., Patel, R., Zehngbot, L., Allen, H., Bosserman, L., DiCarlo, B., Kennedy, et al
2020; 11 (1): 5824
- **Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.** *JAMA*
Kurian, A. W., Bernhisel, R. n., Larson, K. n., Caswell-Jin, J. L., Shadyab, A. H., Ochs-Balcom, H. n., Stefanick, M. L.
2020; 323 (10): 995-97

- **Re: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative Response** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Caswell-Jin, J. L., Kurian, A. W.
2019; 111 (8): 874
- **Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.** *Nature*
Rueda, O. M., Sammut, S., Seoane, J. A., Chin, S., Caswell-Jin, J. L., Callari, M., Batra, R., Pereira, B., Bruna, A., Ali, H. R., Provenzano, E., Liu, B., Parisien, et al
2019
- **Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.** *JAMIA open*
Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., Tamang, S. R.
2019; 2 (4): 528–37
- **Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., Kurian, A. W.
2019; 111 (1): 95–98
- **Chromatin regulators mediate anthracycline sensitivity in breast cancer.** *Nature medicine*
Seoane, J. A., Kirkland, J. G., Caswell-Jin, J. L., Crabtree, G. R., Curtis, C. n.
2019
- **Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.** *Nature communications*
Caswell-Jin, J. L., McNamara, K. n., Reiter, J. G., Sun, R. n., Hu, Z. n., Ma, Z. n., Ding, J. n., Suarez, C. J., Tilk, S. n., Raghavendra, A. n., Forte, V. n., Chin, S. F., Bardwell, et al
2019; 10 (1): 657
- **Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer.** *JCO clinical cancer informatics*
Banerjee, I. n., Bozkurt, S. n., Caswell-Jin, J. L., Kurian, A. W., Rubin, D. L.
2019; 3: 1–12
- **Response to Peshkin, Isaacs, and Schwartz.** *Journal of the National Cancer Institute*
Caswell-Jin, J. L., Kurian, A. W.
2019
- **Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.** *JAMIA Open*
Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., Tamang, S. R.
2019
- **Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.** *JNCI cancer spectrum*
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., Kurian, A. W.
2018; 2 (4): pky062
- **Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?** *JCO precision oncology*
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
2018; 2: 1-10
- **Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?** *JCO Precision Oncology*
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
2018
- **Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.** *Genetics in medicine : official journal of the American College of Medical Genetics*
Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W.
2017
- **Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.** *Journal of oncology practice / American Society of Clinical Oncology*

Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., Hofmann, L. V., Neal, J. W., Telli, M. L.
2016; 12 (8): 763-764

- **Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors** *HUMAN MOLECULAR GENETICS*
Caswell, J. L., Camarda, R., Zhou, A. Y., Huntsman, S., Hu, D., Brenner, S. E., Zaitlen, N., Goga, A., Ziv, E.
2015; 24 (25): 7421-7431
- **Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients** *NATURE COMMUNICATIONS*
Ziv, E., Dean, E., Hu, D., Martino, A., Serie, D., Curtin, K., Campa, D., Aftab, B., Bracci, P., Buda, G., Zhao, Y., Caswell-Jin, J., Diasio, et al
2015; 6
- **Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25** *NATURE COMMUNICATIONS*
Fejerman, L., Ahmadiyeh, N., Hu, D., Huntsman, S., Beckman, K. B., Caswell, J. L., Tsung, K., John, E. M., Torres-Mejia, G., Carvajal-Carmona, L., Echeverry, M. M., Tuazon, A. M., Ramirez, et al
2014; 5
- **High mammographic density in women of Ashkenazi Jewish descent** *BREAST CANCER RESEARCH*
Caswell, J. L., Kerlikowske, K., Shepherd, J. A., Cummings, S. R., Hu, D., Huntsman, S., Ziv, E.
2013; 15 (3)
- **8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Ahmadiyeh, N., Pomerantz, M. M., Grisanzio, C., Herman, P., Jia, L., Almendro, V., He, H. H., Brown, M., Liu, X. S., Davis, M., Caswell, J. L., Beckwith, C. A., Hills, et al
2010; 107 (21): 9742-9746
- **Analysis of chimpanzee history based on genome sequence alignments** *PLOS GENETICS*
Caswell, J. L., Mallick, S., Richter, D. J., Neubauer, J., Gnerre, C. S., Gnerre, S., Reich, D.
2008; 4 (4)